PLAUR and neoplasm: Having documented no adverse events from eBAT or meBAT in immunodeficient, tumor-bearing mice, we next evaluated the potential toxicity associated with these drugs in the setting of tumor-bearing immunocompetent wildtype mice or mice that had genome-wide uPAR deficiency.